ARC Desk

Antibody Drug Conjugate Market Projected to Cross $10.1 Billion by 2026

Lehdistötiedote   •   Elo 30, 2019 09:17 EEST

The global Antibody Drug Conjugate Market size is estimated to reach at US$ 10.1 billion by 2026, registering a CAGR of 26.3% from 2018 to 2026, according to a new study by Acumen Research and Consulting.

Market Overview:

Antibody Drug Conjugate Market 2018 - 2026 research report includes the SWOT analysis that's Strengths, Weakness, Opportunities and Threats which provides you complete analysis of competitors, market growth, market share and in addition as CAGR comparison by region. The report provides analysis of the global Antibody Drug Conjugate Market for the period from 2016 to 2026, wherein 2018–2026 is the forecast period and 2018 is the base year. Data for 2017 has been included as historical information.

The report covers all trends and technologies expected to play a major role in growth of the global Antibody Drug Conjugate Market during the forecast period. It highlights drivers, restraints, and opportunities expected to influence the market from 2018 to 2026. The study provides a holistic perspective on the Antibody Drug Conjugate Market, in terms of revenue (in US$ Mn) and volume (in million units), across different regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South America. The report highlights key trends affecting the Antibody Drug Conjugate Market at the global level. Prominent countries/sub-regions covered in the report include the U.S., Canada, Germany, France, the U.K., Italy, Russia, India, China, Japan, South Korea, South East Asia, GCC, South Africa, and Brazil.

Download Free Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1046

The report comprises detailed ecosystem analysis, which provides a comprehensive view of the global Antibody Drug Conjugate Market. Porter’s five forces model has also been included to help understand the competition landscape of the market. Additionally, current indicators of diverse macro-economic factors are contextualized under key market indicators.

The report also analyzes the Antibody Drug Conjugate Market on the basis of various segments. A unique section in the report also offers a detailed breakdown on the basis of route of administration – which one is highly preferred and which one is minimally preferred.

Scope of the Antibody Drug Conjugate Market Report:

The study provides a decisive view of the Antibody Drug Conjugate Market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Market Segmentation:

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Market Participants / Key Players:

Few of the main player present in the global Antibody drug conjugate market are AbbVie Inc.; Seattle Genetics, Inc.; F. Hoffmann-La Roche Ltd.; Takeda Pharmaceutical Company Limited and Pfizer Inc.

Key Questions Answered in the Report

The report addresses key questions concerning the market evolution and overarching trends shaping global market growth. Some of the key questions answered in the report include-

What is the overall structure of the market?

What was the historical value and what is the forecasted value of the market?

What are the key product level trends in the market?

What are the market level trends in the market?

Which of the market players are leading and what are their key differential strategies to retain their stronghold?

Which are the most lucrative regions in the market space?

Research Methodology

Secondary research sources that are typically referred to include, but are not limited to company websites, annual reports, financial reports, broker reports, investor presentations, SEC filings, internal and external proprietary databases, relevant patent and regulatory databases, national government documents, statistical databases, market reports, news articles, press releases, webcasts specific to companies operating in the market, national government documents, statistical databases, and Factiva.

Primary research involves e-mail interactions, telephonic interviews, and face-to-face interviews conducted for each market segment across geographies. ARC conducts primary interviews on an ongoing basis with market participants and commentators in order to validate the data and analysis. Primary interviews provide firsthand information on market size, market trends, growth trends, competition landscape, and market outlook. These help validate and strengthen secondary research findings. They also help develop the analysis team’s expertise and market understanding.

VIEW FULL RESEARCH REPORT@ https://www.acumenresearchandconsulting.com/antibody-drug-conjugate-market

TABLE OF CONTENT 

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Antibody Drug Conjugate
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Antibody Drug Conjugate Market By Application
1.2.2.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.2.2. Global Antibody Drug Conjugate Market Revenue Share By Application in 2017
1.2.2.3. Blood Cancer
1.2.2.4. Breast Cancer
1.2.2.5. Ovarian Cancer
1.2.2.6. Lung Cancer
1.2.2.7. Brain Tumor
1.2.2.8. Others
1.2.3. Antibody Drug Conjugate Market By End-user
1.2.3.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison By End-user (2015-2026)
1.2.3.2. Hospitals
1.2.3.3. Clinics
1.2.3.4. ASC
1.2.3.5. Homecare
1.2.3.6. Others
1.2.4. Antibody Drug Conjugate Market By Technology
1.2.4.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison By Technology (2015-2026)
1.2.4.2. Cleavable Linker
1.2.4.3. Non-cleavable Linker
1.2.4.4. Others
1.2.5. Antibody Drug Conjugate Market by Geography
1.2.5.1. Global Antibody Drug Conjugate Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Antibody Drug Conjugate Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Antibody Drug Conjugate Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Antibody Drug Conjugate Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Antibody Drug Conjugate Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Antibody Drug Conjugate Major Manufacturers in 2017

CHAPTER 4. ANTIBODY DRUG CONJUGATE MARKET BY APPLICATION

4.1. Global Antibody Drug Conjugate Revenue By Application
4.2. Blood Cancer
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Breast Cancer
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Ovarian Cancer
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Lung Cancer
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Brain Tumor
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Other
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. ANTIBODY DRUG CONJUGATE MARKET BY END-USER

5.1. Global Antibody Drug Conjugate Revenue By End-user
5.2. Hospitals
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Clinics
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. ASC
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Homecare
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Others
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. ANTIBODY DRUG CONJUGATE MARKET BY TECHNOLOGY

6.1. Global Antibody Drug Conjugate Revenue By Technology
6.2. Cleavable Linker
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Non-cleavable Linker
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Others
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

7.1. North America Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Antibody Drug Conjugate Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

8.1. Europe Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

9.1. Asia-Pacific Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

10.1. Latin America Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

11.1. Middle East Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA ANTIBODY DRUG CONJUGATE MARKET BY COUNTRY

12.1. Africa Antibody Drug Conjugate Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Antibody Drug Conjugate Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. AbbVie Inc.
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Seattle Genetics, Inc.
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. F. Hoffmann-La Roche Ltd.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Takeda Pharmaceutical Company Limited
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Pfizer Inc.
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Others
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1046

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.